A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.

The Lugano 2014 criteria are the standard for response assessment in lymphoma. We compared the prognostic performance of Lugano 2014 and the more recently developed response evaluation criteria in lymphoma (RECIL 2017), which relies primarily on computed tomography and uses unidimensional measurements, in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) from the phase III GOYA and GALLIUM trials, respectively. Concordance between responses according to the Lugano 2014 and RECIL 2017 criteria was analyzed. Landmark analyses of progression-free survival (PFS) and overall survival (OS) by end of treatment (EOT) and end of induction (EOI) response status according to RECIL 2017 and Lugano 2014 criteria, and prognostic value of response at EOT/EOI were also compared. Overall, 1333 patients were included from GOYA and 502 from GALLIUM. Complete response (CR) status according to RECIL 2017 criteria showed high concordance with complete metabolic response (CMR) status by Lugano 2014 criteria in both GOYA (92.5%) and GALLIUM (92.4%). EOT and EOI CR/CMR status by both criteria was highly prognostic for PFS in GOYA (RECIL 2017 [CR]: hazard ratio [HR], 0.35 [95% confidence interval [CI] 0.26-0.46]; Lugano 2014 [CMR]: HR, 0.35 [95% CI 0.26-0.48]; both

Informations de copyright

© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

Lale Kostakoglu is a consultant at F. Hoffmann‐La Roche Ltd, Genentech, Inc. and reports consulting and honoraria fees from F. Hoffmann‐La Roche Ltd. Maurizio Martelli has served on a consulting and advisory board and speaker's bureau for F. Hoffmann‐La Roche Ltd, Janssen, Novartis, Gilead Sciences and Sandoz; and reports travel, accommodations and other expenses from F. Hoffmann‐La Roche Ltd. Laurie H. Sehn reports research funding from F. Hoffmann‐La Roche Ltd and Genentech, Inc. and consulting and honoraria fees from F. Hoffmann‐La Roche Ltd, Genentech, Inc., AbbVie, Amgen, Apobiologix, Acerta, AstraZeneca, Celgene, Gilead Sciences, Janssen, Kite Pharma, Karyopharm, Lundbeck, Merck, MorphoSys, Seattle Genetics, Takeda, Teva, TG Therapeutics and Verastem. Andrew Davies reports research funding from F. Hoffmann‐La Roche Ltd and Genentech, Inc, AstraZeneca/Acerta Pharma, MSD and consulting and honoraria fees from F. Hoffmann‐La Roche Ltd, Genentech, Inc., AbbVie, Acerta/AstraZeneca, Celgene, Genmab, Gilead Sciences, Kite Pharma and Incyte. Marek Trněný reports honoraria and consulting fees from Janssen, Gilead Sciences, Bristol‐Meyers Squibb, Amgen, AbbVie, Takeda, F. Hoffmann‐La Roche Ltd, MorphoSys and Incyte; consulting for Celgene; and travel, accommodation and other expenses from AbbVie, Gilead Sciences, Bristol‐Meyers Squibb, Takeda, F. Hoffmann‐La Roche Ltd and Janssen. Michael Herold reports a consultancy/advisory role with Celgene, Gilead and F. Hoffmann‐La Roche Ltd and research funding from F. Hoffmann‐La Roche Ltd. Umberto Vitolo reports a consulting or advisory role for Janssen, Celgene, Juno Therapeutics, Kite Pharma, Genmab and Incyte; speaker's bureau fees from F. Hoffmann‐La Roche Ltd, Janssen, Celgene, Gilead Sciences, Servier and AbbVie; research funding from Celgene; and travel, accommodations or other expenses from Celgene, F. Hoffmann‐La Roche Ltd and AbbVie. Wolfgang Hiddemann reports honoraria from F. Hoffmann‐La Roche Ltd, Janssen, Gilead Sciences and Celgene; a consulting/advisory role for F. Hoffman‐La Roche Ltd, Janssen and Gilead Sciences; speakers’ bureau for F. Hoffmann‐La Roche Ltd, Janssen and Gilead Sciences; research funding from F. Hoffmann‐La Roche Ltd, Janssen and Bayer; and travel expenses/accommodation from F. Hoffmann‐La Roche Ltd, Janssen and Gilead Sciences. Judith Trotman reports research funding from F. Hoffmann‐La Roche Ltd, BMS, BeiGene, Pharmacyclics, Janssen and Cellectar. Andrea Knapp is employed by and has equity ownership interests in F. Hoffmann‐La Roche Ltd. Federico Mattiello is an employee of F. Hoffmann‐La Roche Ltd. Tina G. Nielsen is an employee and stockholder of F. Hoffmann‐La Roche Ltd. Deniz Sahin is an employee and stockholder of F. Hoffmann‐La Roche Ltd. Gila Sellam is an employee and stockholder of F. Hoffmann‐La Roche Ltd. Carol Ward is an employee and stockholder of F. Hoffmann‐La Roche Ltd. Anas Younes is employed by and has stock and other ownership interests in AstraZeneca; has received honoraria from Merck, F. Hoffmann‐La Roche Ltd, Takeda, Janssen, AbbVie, Curis and Epizyme; reports a consulting or advisory role with Bio‐Path Holdings Inc, Xynomic Pharma, Epizyme, F. Hoffmann‐La Roche Ltd, Celgene and HCM; has received research funding from Janssen, Curis, F. Hoffmann‐La Roche Ltd, Genentech, Inc., Merck, Bristol‐Myers Squibb, Syndax; and other relationship with AstraZeneca.